抗病毒治疗可延迟或避免用于相当比例的白种人HBeAg阴性灰区患者
该回顾性分析纳入287例HBeAg阴性患者,按HBV-DNA和ALT水平分为IC及GZ-1至GZ-3组,中位随访8.2年。结果显示未治疗情况下多数白种人GZ患者长期结局良好,HBsAg清除率约15%,仅18例(6.3%)进展为HBeAg阴性慢性乙型肝炎,无肝硬化或进展期纤维化发生。
要点
- 中位随访8.2年,约15%的IC或GZ患者发生HBsAg清除。
- 仅18例(6.3%)GZ患者进展为HBeAg阴性慢性乙型肝炎,无肝硬化或进展期纤维化发生。
- HBV基因分型和HBsAg水平可能有助于预测结局并更好分类GZ患者。
核心结论
- 多数白种人GZ患者在未治疗情况下长期结局良好,HBsAg清除率高而进展为HBeAg阴性慢性乙型肝炎的比例低。
- HBV基因分型和HBsAg水平可能有助于预测结局并更好地分类GZ患者。
研究设计与样本
- 回顾性分析287例HBeAg阴性IC和GZ患者,基线按HBV-DNA和ALT水平分为4组:HBV-DNA<2000 IU/mL且ALT<40 U/L为IC组,HBV-DNA<2000 IU/mL且ALT 40-80 U/L为GZ-1组,HBV-DNA 2000-20000 IU/mL且ALT<40 U/L为GZ-2组,HBV-DNA 2000-20000 IU/mL且ALT 40-80 U/L为GZ-3组。
- 数据亦采用AASLD ALT标准进行分析。
主要发现
- 中位随访8.2(5-19)年,约15%的IC或GZ患者发生HBsAg清除。
- 40%的GZ患者转为IC状态。
- DNA波动>2000 IU/mL与转为IC状态及HBsAg清除呈负相关。
- IC组HBsAg水平显著低于GZ组(338 IU/mL [20-3269] vs 5763 IU/mL [2172-17754];P<0.05),GZ组内从GZ-1至GZ-3患者HBsAg水平呈递增梯度(P<0.05)。
- 仅18例(6.3%)GZ患者进展为HBeAg阴性慢性乙型肝炎,无患者发生肝硬化或进展期纤维化。
关键数值与推荐
- GZ定义为介于IC状态与HBeAg阴性慢性乙型肝炎之间的患者,基线分组标准为HBV-DNA<2000 IU/mL或2000-20000 IU/mL,ALT<40 U/L或40-80 U/L。
- 数据亦采用AASLD ALT标准进行分析。
临床怎么用
- 原文结论认为多数白种人GZ患者在未治疗情况下长期结局良好,抗病毒治疗可延迟或避免用于相当比例的患者。
- 作者认为HBV基因分型和HBsAg水平可能有助于预测结局并更好地分类GZ患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Grey Zone (GZ) is an ill-defined situation including patients falling between inactive carrier (IC) state and HBeAg-negative chronic hepatitis B (HBeAg-negative CHB). AIMS: To assess the long-term outcomes of GZ patients compared to IC in the absence of treatment. METHODS: Retrospective analysis of 287 IC and GZ HBeAg-negative patients. Patients were classified into 4 groups at baseline: HBV-DNA <2000 IU/mL and ALT <40 U/L (IC), HBV-DNA <2000 IU/mL and ALT 40-80 U/L (GZ-1), HBV-DNA 2000-20 000 IU/mL and ALT <40 U/L (GZ-2) or ALT 40-80 U/L (GZ-3). Data were also analysed using AASLD ALT criteria. RESULTS: After a median follow-up of 8.2 (5-19) years, HBsAg loss occurred in about 15% ICs or GZ patients. Transition into IC state occurred in 40% of GZ patients. DNA fluctuations >2000 IU/mL correlated inversely with transition into IC and HBsAg loss. HBsAg levels were significantly lower in ICs than in GZ patients (338 IU/mL [20-3269] vs 5763 IU/mL [2172-17 754]; P < 0.05). Among the latter group, there was an increasing gradient of HBsAg levels from GZ-1 to GZ-3 patients (P < 0.05). HBeAg-negative CHB occurred in only 18 (6.3%) GZ patients. No patient developed cirrhosis nor advanced fibrosis. ALT/HBV-DNA fluctuations and HBeAg-negative CHB development were more frequent in genotype B/C patients, whereas HBsAg loss occurred only in genotype A/D patients. CONCLUSIONS: Most Caucasian GZ patients present excellent long-term outcomes in the absence of treatment, with a high rate of HBsAg loss and low rate of progression to HBeAg-negative CHB. HBV-genotyping and HBsAg levels could help to predict outcomes and better classify GZ patients.
引用
- Bonacci M, Lens S, Mariño Z, et al. Anti-viral therapy can be delayed or avoided in a significant proportion of HBeAg-negative Caucasian patients in the Grey Zone. Aliment Pharmacol Ther. 2018. PMID: 29577350. doi:10.1111/apt.14613
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。